Clinical Trial Update: A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tislelizumab with chemoradiotherapy followed by tislelizumab alone in newly diagnosed, stage III unresectable non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2020-07-15